title: [Medical treatment of the uterine miomas in perimenopausal patients].
abstract: BACKGROUND
  Leiomyomas are the most common benign tumors of the uterus, frequently associated with abnormal uterine bleeding. Medroxyprogesterone (MP) acetate it is a therapeutic alternative.
  
  
  OBJECTIVE
  To determine the efficacy of the medroxyprogesterone for abnormal uterine bleeding associated with leiomyomatosis in perimenopause women.
  
  
  METHODS
  An observational, prospective, longitudinal study. We selected 31 patients with uterine myomas and abnormal uterine bleeding. Two years monthly doses of 150 mg of MP were given. If the bleeding did not stop at six months of treatment or increased a hysterectomy was performed.
  
  
  RESULTS
  Two (6.4%) patients abandoned the treatment after a first doses; 21 (67.7%) completed the treatment without uterine bleeding (efficacy observed of 72.4%; CI 95% 54.4 to 90.4%, intention to treat efficacy 67.7%, CI 95% 49.6 to 86.8%). Eight (25.8%) patients persisted with uterine bleeding before 6 months of treatment and a hysterectomy was performed. There was no severity secondary effect informed.
  
  
  CONCLUSIONS
  Management with medroxyprogesterone may be an effective treatment to control the uterine bleeding associated with myomatosis. Their use could reduce the necessity of some hysterectomies.
authors.forename: Abraham Jovanny
authors.initials: AJ
authors.lastname: Olvera-Maldonado
authors.forename: Alfonso
authors.initials: A
authors.lastname: Martínez-Uribe
authors.forename: Mario Enrique
authors.initials: ME
authors.lastname: Rendón-Macías
authors.forename: Augusto
authors.initials: A
authors.lastname: Sangines-Martínez
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D007889:Leiomyoma / Q000188:drug therapy* / Q000473:pathology; D008137:Longitudinal Studies; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D008875:Middle Aged; D047648:Perimenopause; D011446:Prospective Studies; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017258:Medroxyprogesterone Acetate